comprehensive -WSS

comprehensive

author：explore 2025-08-23 08:57:01 - browse：7

A liver with a smooth and healthy left half and a bumpy, browning right half — chronic disease coverage from STAT — Adobe

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.

The mid-stage study of the Akero drug called efruxifermin achieved its main goal in September 2022. With longer treatment, more patients with MASH responded to the drug, while those who initially benefited showed durable improvements.

“We’re really pleased with the data. It’s exactly what we were hoping to see,” said Kitty Yale, Akero’s chief development officer, in an interview with STAT. “It’s not just the high response rates, but the fact that responses are sustained and broadened as well.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Clinical trials giant ICON acquires HumanFirst

focus

WSS

Florida officials tell state schools to teach AP Psychology 'in its entirety'

FDA scientists endorse Pfizer/BioNTech Covid

When waiting feels immoral: Empathy in the emergency department

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

Chris Christie meets with Zelenskyy during Ukraine trip

focus

comprehensive

knowledge

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

An inside look at PIPEs, biotech's buzzy new financing tool

In Memoriam: Notable people who died in 2023

Chris Christie meets with Zelenskyy during Ukraine trip

What does generative AI mean for health care? We asked experts

Physicians aren't 'burning out.' They're suffering from moral injury

Duchenne breakthrough therapy leaves behind pioneering families

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Trump demands the U.S. pay no more for drugs than other countries … again

Late stage cancers on the rise after pandemic delayed screenings

explore

'Null' research findings aren't empty of meaning. Let's publish them

Chris Christie meets with Zelenskyy during Ukraine trip

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

How I helped Pfizer think through the ethics of Viagra

Heart disease in astronauts blamed on cosmic radiation

FogPharma raises $145 million in rare Series E round

focus

entertainment

focus

focus